Search Labs

We use genetic systems to deconstruct functions associated with the most commonly mutated genes found in human cancers.

Harnessing the power of light to develop methods to understand, diagnose, & treat diseases. The unique strength of the Achilefu Lab (Optical Radiology Lab, ORL) is the ability to develop complete solutions from conception, implementation, and validation to human clinical care. We aim to change the way medicine is practiced.

The Acute Liver Failure Study Group (ALFSG) is a clinical research network funded by the National Institutes of Health since 1997, to gather important prospective data and biosamples on this rare condition. 

The Advanced Imaging and Informatics for Radiation Therapy (AIRT) Lab's research is focused on the development of novel imaging and beam delivery techniques and new machine learning algorithms to improve the efficacy of radiation therapy.

The focus of Dr. Agarwal's research has been on mechanisms of steroid action with emphases on: 1) structure-activity relationships of ligand-steroid receptor interactions, and 2) steroid metabolism.

Our lab is using various approaches to explore this biology and develop new treatments with a focus on targeting tumor intrinsic factors such as genetic programs like the epithelial to mesenchymal transition that coordinate with infiltrating immune cells in enhance therapeutic resistance and assist distant spread.

Akbay Lab studies genetic and molecular events that lead to lung-tumor initiation and immune evasion. 

Our mission is to improve the care of breast cancer patients through cutting-edge translational research at the interface of clinical oncology, cancer biology, molecular genetics, and translational genomics.

Our goal is to track the signaling dynamics of individual effectors and toxins in living cells, using a combination of fluorescent genetic reporters, microinjection of labeled bacterial proteins, and live cell imaging techniques. 

Our group initially investigated a novel immune checkpoint inhibitor targeting a rare heparan sulfate (rHS) in melanoma treatment. Collaboratively, we explored the potential of a single-domain humanized rHS antibody (1A7 clone) that inhibits DC-HIL function and also angiogenesis and chemokine effects linked to diverse cancer progression signaling pathways. This experience provided insights into rHS-targeting as a promising approach to melanoma therapy.

The Arteaga laboratory has a longstanding interest in understanding the molecular pathways that drive breast cancer progression and influence response to therapies.

Multidisciplinary research to beat cancer